Product Description: Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants[1][2].
Applications: COVID-19-anti-virus
Formula: N/A
References: [1]Ji Y, et, al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. /[2]Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drug. 2022 Aug;82(12):1327-1331.
CAS Number: 2509447-07-6
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Infection
Solubility: H2O
Target: SARS-CoV